AZ hopes data will boost sales of its Farxiga.
Balancing innovation and huge unmet patient need with burgeoning cost constraints.
Lilly/Boehringer gain further advantage in US diabetes market.
Sanofi under pressure following long-awaited biosimilar launch.
Companies’ actions discredited the industry, says PMCPA.
Long-release pill is eighth drug to come from diabetes partnership.
Partnership will seek to develop two immune checkpoint inhibitor candidates.